Patents Assigned to IDEC PHARMACEUTICALS
  • Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
    Publication number: 20030180292
    Abstract: The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias, as well as other CD40+ malignancies. The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interaction. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies, chemotherapeutic agents, chemotherapy cocktails, and radiotherapy.
    Type: Application
    Filed: March 14, 2002
    Publication date: September 25, 2003
    Applicant: IDEC PHARMACEUTICALS
    Inventors: Nabil Hanna, Kandasamy Hariharan
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030082172
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: March 14, 2002
    Publication date: May 1, 2003
    Applicant: IDEC PHARMACEUTICALS
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter